Implications of recent FDA Guidance based on pCR in Early Breast Cancer
Soumi Lahiri, GlaxoSmithKline *Ram Suresh, GlaxoSmithKline Keywords: 'Singe trial 'vs 'Multiple-trials' The current path to drug approval in early breast cancer takes too long, especially impacting high-risk patients with potential cure. The recent guidance issued by the FDA to the industry is a major step forward. However, there are several issues that still need to be resolved and these are being actively discussed in multiple forums. The challenges in design and implementation of early trials to support registration for Early Breast Cancer will be discussed. The intricacies of ‘single-trial’ versus ‘multiple-trials’ approaches and the impact of later therapies in establishing long-term benefit of neo-adjuvant treatments in clinical trials will be discussed
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC